255 results about "Nasopharyngeal cancer" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The invention discloses an S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound, a preparation method and application thereof. The compound has a structural general formula shown as formula I. The S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound has an obvious control effect on potato late blight, cucumber fusarium wilt, Botrytis cinerea Pers, Pepper Phytophthora blight, rice sheath blight, wheat scab, Colletotrichum musae, asparagus stem blight and the like, and can be used as an agricultural fungicide in control of plant diseases. At the same time, the compound has an inhibitory effect on HL-60 human leukemia cells, MCF-7 human breast cancer cells, BGC-823 human gastric cancer cells, Bel-7402 human hepatocellular carcinoma cells, and KB human nasopharyngeal carcinoma cells, etc., and has application prospects in the aspect of anti-tumor activity. (formula I).

The invention relates to an automatic design method for a nasopharyngeal carcinoma radiotherapy plan based on machine learning, and provides a method for searching for a patient optimal objective function based on Overlap Volume Histogram (OVH) data and in combination with machine learning nearest neighbor method. The method comprises establishing a template library by using existing data, searching for the most similar cases in the OVH data and the template library of newly enrolled patients by using the machine learning nearest neighbor method, and planning the radiotherapy plan of the newlyenrolled cases by using the objective function of the searched radiotherapy plan of the newly enrolled cases. The case template is searched without the need for human subjective factors, and the patient's nasopharyngeal carcinoma radiotherapy plan is automatically designed.

The invention discloses an oral Chinese herbal compound for treating nasopharyngeal darcinoma, belonging to the Chinese traditional medicine. The oral Chinese herbal compound for treating nasopharyngeal darcinoma is prepared with the following weights of raw materials: 40g of gypsum, 6g of processed rhubarb, 5g of szechwan lovage rhizome, 4g of cicada slough, 30g of radix rehmanniae, 30g of figwort, 10g of cortex moutan, 10g of licorice products, 10g of honeysuckle, 20g of prunella vulgaris and 6g of liquorice. The herbs are decocted in water for oral taking; one dose of the decoction is taken in one day; each dose is decocted for two times and separated for taking in the morning and in the evening. The oral Chinese herbal compound for treating nasopharyngeal is reasonable in prescription, convenient in preparation, used for remedying incomplete treatment to the nasopharyngeal and various side effects by radiochemotheraphy, and evident for the treatment effect.

The invention provides an application of a YH1 protein to combination and agglutination of pathogenic microorganisms, provides an application of the YH1 protein to preparation of a medicament for treating inflammation-relevant diseases caused by bacterial infection, and discloses a preparation method of the YH1 protein. The method comprises the following steps of: constructing an expression vector; constructing expression engineering bacteria; and performing induced expression, purification and enzyme digestion. A recombinant YH1 protein obtained with the method has bioactivity. According to the recombinant YH1 protein, pathogenic microorganisms can be combined and agglutinated, so that the YH1 protein plays a role in killing gram negative bacteria, and can be used for preventing and treating inflammation caused by bacterial infection.

The invention discloses an aromatic hydrocarbon ruthenium complex and an application thereof as an antitumor drug. For the aromatic hydrocarbon ruthenium complex, methyl benzene is taken as a ligand, phenanthro-imidazole and derivatives of phenanthro-imidazole are taken as the second ligand, and a chlorine atom is taken as the third ligand. The complex can inhibit the propagation, invasion and metastasis of tumor cells, has an especially good effect on inhibiting growth of cells of breast cancer, brain glioma, leukemia, nasopharyngeal carcinoma, and pulmonary adenocarcinoma, and barely damages the normal cells of human body. The invention also discloses a preparation and applications of the aromatic hydrocarbon ruthenium complex.

The invention provides a nasopharyngeal cancer artificial intelligence auxiliary diagnosis and treatment decision terminal. The diagnosis and treatment decision terminal performs data interaction witha diagnosis and treatment decision server cluster in response to a user instruction, and provides a diagnosis decision service for a user in a visual manner; and the diagnosis and treatment decisionterminal is configured to select a first model, a second model, a third model, a fourth model, and / or a fifth model to provide a diagnosis decision service for the user. The nasopharyngeal cancer artificial intelligence auxiliary diagnosis and treatment decision terminal can provide an accurate intelligent diagnosis decision service based on artificial intelligence for the user and have broad application prospects.

The present invention relates to the use of a compound of formula 3 or a salt thereof for preparing a medicament or a phototherapeutic agent for the treatment of the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; atypical pneumonia virus infection; coronary Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophagus cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary duct cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancers. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of a compound of formula 3 or a salt thereof for the preparation of a photodiagnostic agent for the detection of the above-mentioned diseases and diseases including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infection, viral infection, chlamydia infection, bacterial infection, or parasitic infection, HIV infection, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease and skin disease. The present invention also relates to methods of detecting the above diseases using photodiagnostic agents. The present invention further relates to a method of cryogenically sterilizing a surgical device or other device, comprising the steps of: providing a compound of formula 3 or a salt thereof on the device; subjecting the device to radiation treatment or sonication. The present invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The present invention also relates to the use of such MRI enhancers for performing MRI scans.